Who Paid My Doc
Richard Scher
Little Silver, NJ Doctor of Osteopathy
NPI 1043205313 CMS profile 46796
180 White Rd, Suite 101, Little Silver, NJ 07739
General payments
$7,420
Research payments
$0
Ownership & investment interest
$30,000
Through program year 2025, Richard Scher of Little Silver, NJ is reported in the CMS Open Payments database as having received $7,420 across 28 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $30,000 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $85 | 5 | |
| 2024 | General | $2,688 | 8 | |
| 2023 | General | $16 | 1 | |
| 2022 | General | $27 | 2 | |
| 2021 | General | $1,275 | 3 | |
| 2020 | General | $1,102 | 2 | |
| 2019 | General | $2,227 | 7 | |
| 2024 | Ownership | $5,000 | 1 | |
| 2023 | Ownership | $5,000 | 1 | |
| 2022 | Ownership | $5,000 | 1 | |
| 2021 | Ownership | $5,000 | 1 | |
| 2020 | Ownership | $5,000 | 1 | |
| 2019 | Ownership | $5,000 | 1 |
Beside peers
- Richard Scher
- New Jersey median
- Middle half of New Jersey
- National median
In program year 2025, general payments to Richard Scher were reported at $85. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.
Show as a table
| Year | Richard Scher | New Jersey median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,227 | $150 | $44–$542 | $163 |
| 2020 | $1,102 | $110 | $33–$349 | $114 |
| 2021 | $1,275 | $125 | $36–$419 | $132 |
| 2022 | $27 | $142 | $42–$480 | $149 |
| 2023 | $16 | $156 | $48–$510 | $160 |
| 2024 | $2,688 | $167 | $50–$562 | $164 |
| 2025 | $85 | $178 | $51–$585 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
592
Drug cost
$1,408,254
Branded share of claims
46.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 49 | $693,230 | |
| Cabometyx Cabozantinib S-Malate | Brand | 11 | $273,559 | |
| Lenalidomide | Generic | 13 | $186,187 | |
| Xarelto Rivaroxaban | Brand | 87 | $84,420 | |
| Imbruvica Ibrutinib | Brand | 12 | $70,202 | |
| Eliquis Apixaban | Brand | 62 | $49,268 | |
| Imatinib Mesylate | Generic | 29 | $46,963 | |
| Valacyclovir Valacyclovir Hcl | Brand | 52 | $1,496 | |
| Letrozole | Generic | 50 | $748 | |
| Potassium Chloride | Generic | 21 | $484 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 145 billing codesPaid by Medicare
$3,128,147
Medicare patients
591
Services billed
151,003
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Ischemic heart disease | 45% | |
| Cancer | 39% | |
| Chronic kidney disease | 35% | |
| Diabetes | 33% | |
| Heart failure | 28% | |
| Atrial fibrillation | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 11 | 9,400 | $420,099 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 14 | 9,720 | $384,903 |
| Injection, denosumab, 1 mg J0897 | Office | 23 | 2,100 | $43,079 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 22 | 2,800 | $42,866 |
| Injection, aprepitant, 1 mg J0185 | Office | 12 | 4,680 | $6,206 |
| Vaccine for influenza for injection into muscle 90653 | Office | 51 | 51 | $4,173 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 15 | 927 | $3,242 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 12 | 9,000 | $1,033 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 31 | 1,190 | $816 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 11 | 70 | $293 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| IMFINZI |
|
$400 | — | — |
| LIBTAYO |
|
$51 | — | — |
| KRAZATI |
|
$14 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.